-
-
-
-
-
-
-
Mizuho on Boston Scientific (BSX): 'we do not foresee any FTC risk concerns'
-
-
-
-
-
-
-
Nephron Downgrades Penumbra (PEN) to Hold
-
-
-
-
-
-
-
Morgan Stanley on Boston Scientific (BSX): 'Stock is looking too cheap and has clear catalysts'
-
-
-
-
-
-
-
JPMorgan Upgrades Penumbra (PEN) to Overweight
-
-
-
-
-
-
-
Penumbra trial shows thrombectomy device outperforms standard treatment
-
-
-
-
-
-
-
Penumbra (PEN) PT Raised to $350 at Canaccord Genuity
-
-
-
-
-
-
-
Penumbra, Inc. (PEN) Tops Q1 EPS by 16c, reiterates guidance
-
413,532 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

